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The key role played by Fgf10 during early lung development is clearly illustrated in Fgf10 knockout mice, which exhibit lung agenesis.
However, Fgf10 is continuously expressed throughout lung development suggesting extended as well as additional roles for FGF10 at later
stages of lung organogenesis. We previously reported that the enhancer trap Mlcv1v-nLacZ-24 transgenic mouse strain functions as a reporter
for Fgf10 expression and displays decreased endogenous Fgf10 expression. In this paper, we have generated an allelic series to determine
the impact of Fgf10 dosage on lung development. We report that 80% of the newborn Fgf10 hypomorphic mice die within 24 h of birth due
to respiratory failure. These mutant mouse lungs display severe hypoplasia, dilation of the distal airways and large hemorrhagic areas.
Epithelial differentiation and proliferation studies indicate a specific decrease in TTF1 and SP-B expressing cells correlating with reduced
epithelial cell proliferation and associated with a decrease in activation of the canonical Wnt signaling in the epithelium. Analysis of vascular
development shows a reduction in PECAM expression at E14.5, which is associated with a simplification of the vascular tree at E18.5. We
also show a decrease in α-SMA expression in the respiratory airway suggesting defective smooth muscle cell formation. At the molecular
level, these defects are associated with decrease in Vegfa and Pdgfa expression likely resulting from the decrease of the epithelial/
mesenchymal ratio in the Fgf10 hypomorphic lungs. Thus, our results indicate that FGF10 plays a pivotal role in maintaining epithelial
progenitor cell proliferation as well as coordinating alveolar smooth muscle cell formation and vascular development.
© 2007 Elsevier Inc. All rights reserved.Keywords: Fgf10 hypomorph; Mesenchymal differentiation; Smooth muscle cells; Lung emphysema; VascularizationIntroduction
Fibroblast growth factor 10 (FGF10) is responsible for directed
outgrowth of the lung endoderm (Bellusci et al., 1997). In the
developing lung, Fgf10 is expressed in the distal mesenchyme at⁎ Corresponding author.
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doi:10.1016/j.ydbio.2007.04.033sites where prospective epithelial buds will appear. Moreover, its
dynamic pattern of expression and its ability to induce epithelial
expansion and budding in organ cultures have led to the
hypothesis that FGF10 governs the directional outgrowth of
lung buds during branchingmorphogenesis (Bellusci et al., 1997).
Furthermore, FGF10 was shown to induce chemotaxis of the
distal lung epithelium (Park et al., 1998; Weaver et al., 2000).
Consistent with these observations, Fgf10 null mutants show
multiple organ defects including lung agenesis (Min et al., 1998;
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FGF10 role during lung development. FGF10 is the main ligand
for fibroblast growth factor receptor 2b (FGFR2b) during
embryonic development as demonstrated by the remarkable
similarity of phenotypes exhibited by embryos where these genes
have been inactivated (Min et al., 1998; Sekine et al., 1999; Burns
et al., 2004; De Moerlooze et al., 2000; Mailleux et al., 2002;
Burns et al., 2004; Del Moral et al., 2006a,b). Moreover,
inhibition of FGFR2b signaling from embryonic day 14.5
(E14.5) onwards using a transgenic mouse line expressing a
soluble FGFR2b (FGFR2b-HFc) under the control of an
inducible lung-specific, Surfactant protein C promoter (SpC-
rtTA), resulted in decreased epithelial morphogenesis before
birth and caused severe emphysema at maturity (Hokuto et al.,
2003). Interestingly, Fgf10 expression level keeps increasing
during lung development between E11.5 and E18.5 (Bellusci et
al., 1997), suggesting that Fgf10 most likely plays an extended
and vital role during late lung organogenesis.
We have previously shown that a transgenic mouse line with
the β-galactosidase gene under the control of Fgf10 regulatory
sequences can be used to monitor Fgf10 expression in the heart,
lung and somites (Kelly et al., 2001; Mailleux et al., 2005;
Veltmaat et al., 2006). Originally, Kelly et al. (2001) sought to
express LacZ under the control of the myocardial ventricular-
slow skeletalmuscleMyosinAlkali-light chain (Mlc1v) promoter.
In one of four founders, the expression pattern in the developing
heart suggested that LacZ was under the control of Fgf10
regulatory sequences. In addition, analysis of the integration site
showed that the Mlc1v-LacZ cassette had integrated 120 kb
upstream of the Fgf10 gene. Based on the expression pattern as
well as on the site of insertion, the authors proposed that LacZ
expression was under the control of Fgf10 regulatory sequences.
We reported that the insertion of the Mlc1v-LacZ cassette
disrupted the endogenous expression of Fgf10 (Mailleux et al.,
2005). TheMlc1v-LacZmice were crossed withFgf10+/−mice to
generate an allelic series to determine the effect of decreasing
Fgf10 expression on parabronchial smoothmuscle cell formation.
We also demonstrated that Fgf10 identifies a new population of
parabronchial smooth muscle cell progenitors located in the sub-
mesothelial mesenchyme (Mailleux et al., 2005).
In this paper, we report our analysis of Fgf10 hypomorphic
(Fgf10+/−;Mlc1v-LacZ+/−) lungs at various developmental
stages. Newborn Fgf10 hypomorphic mice exhibit respiratory
failure and consequently die within 48 h. Analysis shows
severe lung hypoplasia, dilation of the distal airways and large
hemorrhagic areas. Therefore, this mouse represents a unique
opportunity to study the role of FGF10 in coordinating
epithelial morphogenesis with the differentiation of the
mesenchyme, in particular with the formation of alveolar
smooth muscle cells and the vasculature.
Materials and methods
Analysis of LacZ expression
β-galactosidase activity was monitored in whole-mount and histological
samples as described by Kelly et al. (1995). The day of vaginal plug was
considered as embryonic day 0.5 (E0.5). Embryos were dissected in 1× PBS atdesired stages and fixed in 4% PFA. Following fixation, the embryos were
washed in 1× PBS and stained with X-gal solution. Stained lungs were sectioned
(25μm) using a vibratome.
Mutant embryos
The Mlc1v-nLacZ-24 line (called for simplification Mlc1v-LacZ or Mlc1v in
this paper) has been previously described (Kelly et al., 2001). The transgene
containing an nLacZ reporter gene (containing a nuclear localization signal) is
integrated upstream of the Fgf10 gene. Fgf10+/−;Mlc1v-LacZ+/− embryos were
generated by crossing Fgf10+/− and Mlc1v-LacZ+/− mice (Kelly et al., 2001;
Sekine et al., 1999) on a C57BL/6 background. Fgf10+/− littermates were used as
control embryos at different developmental stages. The Fgf10− andMlc1v-LacZ+
alleles were genotyped as described previously (Kelly et al., 2001; Mailleux et al.,
2002). The number of Fgf10+/−;Mlc1v-LacZ+/− embryos used in this study (47 in
total) at the different stages was as follows: E12.5 (n=7), E13.5 (n=3), E14.5
(n=6), E16.5 (n=2), E17.5 (n=10); E18.5 (n=7); PN (n=12).
Real-time RT–PCR
Total RNA was extracted from individual Fgf10+/− and Fgf10+/−; Mlc1v+/−
E14.5 embryonic lungs (n=3 for each genotype) using the RNeasy kit (Gibco
BRL) according to the manufacturer's instructions. DNA contaminations were
removed in the total RNA using Turbo DNAse (Ambion). Total RNA was
reverse-transcribed using the Superscript-III first strand super mix (Invitrogen)
following the manufacturer's recommendations. 5 μg of the total RNAwas used
to prepare cDNA from the isolated total RNA using oligodT primers. 25 pg
cDNA was used for each of the real-time PCR reactions using the primers and
probes designed by the online Roche software: Probe finder version 2.20, https://
www.roche-applied%1Escience.com/sis/rtpcr/upl/adc.jsp. All real-time PCR reac-
tionswere performedwith Roche: FastStart TaqMan®ProbeMaster kits, according
to the manufacturer's instructions in Roche Light Cycler 1.5 Real-Time PCR
machine. 18S ribosomal RNAwas used as an internal control for all analysis.
Analysis of SP-B and TTF-1 expression
Newborn pup lungs (3 Fgf10+/−;Mlc1v-LacZ+/− and 3 control) were fixed
overnight in paraformaldehyde, rinsed in PBS twice for 5min, transferred to 70%
ethanol overnight and stored in 100% ethanol. The samples were then embedded
in paraffin and sections (5 μm) were cut. The number of cells expressing SP-B
and TTF1 was quantified using immunohistochemistry protocol with Envision+
HRP system (Dakocytomation). Alternatively, expression of SP-B was also
determined using in situ hybridization on sections using a specific mouse SP-B
probe (gift from Dr. Jeffrey Whitsett). Positive cells were scored in random
portions of a section in eight photomicrographs (50× magnification). A total
number of 3000 cells were counted per sample. The results are presented as a ratio
of total number of positive cells/total number of cells. Lungs from three mutant
and three control mice were taken at birth.
Antibodies
The following antibodies were used for immunohistochemistry on 5 μm
thick paraffin sections: mouse monoclonal antibody against α-SMA (Sigma) at a
dilution of 1/5000, mouse monoclonal antibody against Phospho-p44/42 MAPK
(cell Signaling: 20G11) at a dilution of 1/50, mouse monoclonal antibody
against Thyroid Transcription factor-1 (NeoMarkers), rabbit polyclonal anti-
body against Surfactant protein B (Chemicon), anti-PECAM/CD31 antibody
(BD Pharmage), anti-Laminin antibodies (Sigma), anti-Elastin polyclonal
antibodies (EPC) at a dilution of 1/200. Slides were mounted with Vectashield
(Vector Labs) containing DAPI. Immunohistochemistry for β-catenin was
performed with the Envision kit from Dako cytomation, β-catenin antibodies
(BD Biosciences) was used at 1:100. Photomicrographs were taken using a
Leica DMRA fluorescence microscope with a Hamamatsu Digital CCD Camera.
Visualization of the vascular system by plastic casting
To visualize the vessels of the vascular system of E18.5 embryonic lung, we
used Batson's #17 Anatomical Corrosion Kit (Polysciences). The pregnant
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abdominal area was opened and 5 U of heparin (1000 U/ml) was injected into the
inferior vena cava. Embryos were then isolated, the sternum exposed and
approximately 4 ml of a methyl methacrylate-based resin was injected into the
right ventricle of the heart. The embryos were cured for 3 h in ice-cold water and
were subsequently soaked in distilled water overnight at 4 °C. Embryos were
then digested in maceration solution using approximately three times volume of
tissue being digested and were incubated at 50 °C for 72 h or until all tissue was
cleared. Maceration solution was changed every 3 h. Images of the cast were
documented using a Leica MZ125 with SPOT v3.2.0 digital camera.
Proliferation
Dehydrated E14.5 and E17.5 lungs (3 Fgf10+/−;Mlc1v-LacZ+/− and 3
controls for each stage) were fixed overnight in paraformaldehyde, rinsed
twice in PBS for 5 min, transferred to 70% EtOH overnight and stored in100% EtOH. The samples were then embedded in paraffin and sections (5 μm)
were cut. The PCNA staining kit (Zymed Labs Inc. 93-1143) was used for
immunostaining. At E14.5, the total numbers of cells in the epithelium as well
as the number of PCNA positive cells in the epithelium were scored in three
photomicrographs (64× magnification), in random portions of a section of
three different mutant and control lungs each. A similar count was done for
mesenchymal cells. At E17.5, as it was no longer possible to distinguish
between epithelium and mesenchyme, the total number of cells versus the total
number of PCNA positive cells were counted for each genotype. A total
number of 3000 cells were counted per sample. The significance in
proliferation between control and hypomorphic lungs was evaluated by one-
tailed paired t-test. P values less than 0.05 were considered to be statistically
significant.
In situ gelatinase assay
In situ zymogram assays were carried out using fluorescein isothyocyanate
labeled gelatin (Molecular Probes, Eugene, OR) to detect gelatinase activity
(corresponding to MMP2 and MMP9 expressed at high levels in the smooth
muscle cells). The reaction product was visualized using fluorescence
microscopy.
Results
Insertion of the Mlc1v-LacZ cassette results in decreased
endogenous Fgf10 expression
We recently published that the insertion of the Mlvc1v-
LacZ cassette 120 kb upstream of the transcriptional start
site of the Fgf10 gene, resulted in a general decrease in
Fgf10 expression in the embryo (Mailleux et al., 2005;
Veltmaat et al., 2006). We took advantage of this
characteristic of the Mlc1v-LacZ line to generate an allelic
series to determine the impact of Fgf10 dosage on lung
development. Mlc1v-LacZ+/− line was crossed with Fgf10neo
null allele heterozygote mice (denoted as Fgf10−) to
generate Fgf10+/+;Mlc1v-LacZ−/− (wild type), Fgf10+/+;
Mlc1v-LacZ+/−, Fgf10+/−;Mlc1v-LacZ−/− (called thereafter
Fgf10+/−) and Fgf10+/−;Mlc1v-LacZ+/− (called also thereafter
Fgf10 hypomorph) embryos at different developmental stages.
As the lungs of embryos corresponding to the first three genotypesFig. 1. Fgf10+/−;Mlc1v-LacZ+/− lungs display reduction in Fgf10 expression and
hypoplasia. (A) Nearly identical Cp values of ribosomal 18S messenger RNA
(mRNA) indicate comparable amounts of starting material (Fgf10+/− Cp=20.26,
Fgf10+/−;Mlc1v-LacZ+/−Cp=20.23). (B) Real-time PCR quantification in E14.5
lungs show a decrease of Fgf10 mRNA in Fgf10+/−;Mlc1v-LacZ+/− lungs
(Fgf10+/− Cp=27.04, Fgf10+/−;Mlc1v-LacZ+/− Cp=27.53). Reduced epithelial
branching in Fgf10+/−;Mlc1v-LacZ+/− vs. control (Fgf10+/−) lungs. (C–F)
Fgf10+/− (control) lung of E12.0 with 4 buds in the left lobe shown at high
magnification. (D) Fgf10+/−;Mlc1v-LacZ+/− lung at E12.0 with 3 buds in the
left lobe. (E) Fgf10+/− (control) lung of E12.5 with 6 buds in the left lobe. (F)
Fgf10+/−;Mlc1v-LacZ+/− lung at E12.5 with 4 buds in the left lobe. (G) Fgf10+/−
(control) lung at E17.5. (H) Hypoplastic E17.5 Fgf10+/−;Mlc1v-LacZ+/− lung
with absent the accessory lobe (white arrow). (I) Whole embryo body weights at
E14.5, E17.5 and newborn (NB) of Fgf10+/− and Fgf10+/−;Mlc1v-LacZ+/−
embryos show significant differences (475.83 mg, 994.40 mg, 1344 mg vs.
440 mg, 881.62 mg, 1188.85 mg, respectively). (J) Embryo/lung weight
ratio at E14.5, E17.5 and newborn (NB) in control (Fgf10+/−) and Fgf10+/−;
Mlc1v-LacZ+/− embryos show significant differences (0.029, 0.035, 0.034 vs.
0.017, 0.019, 0.017, respectively).
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and Fgf10+/−;Mlc1v-LacZ−/− (or Fgf10+/−)) were phenotypically
identical throughout all the developmental stages examined (data
not shown), we considered as control for this study, among these 3
genotypes, the one corresponding to the lowest expression of
Fgf10 (Fgf10+/−). 47 Fgf10+/+;Mlc1v-LacZ+/− compound he-
terozygous embryos were generated at expectedMendelian ratios
and examined at different stages. As expected, real-time PCR
experiments showed that Fgf10 expression is reduced by 27% in
E14.5Fgf10+/−;Mlc1v-LacZ+/− lungs compared to corresponding
Fgf10+/− lungs (Figs. 1A,B; n=3, P=0.005).
Fgf10+/−;Mlc1v-LacZ+/− compound heterozygous embryos
exhibit lung hypoplasia
The Fgf10+/−;Mlc1v-LacZ+/− embryos displayed defects in
lung development. At E12 and E12.5, the lung phenotype wasFig. 2. Fgf10+/−;Mlc1v-LacZ+/− lungs display decreased epithelial proliferation and re
cell proliferation in Fgf10+/− and Fgf10+/−;Mlc1v-LacZ+/− at E14.5 and E17.5. Bla
proliferation of epithelium in mutant lungs at E14.5. (D) At E17.5, a general decrease
introduced in Fgf10+/+;Mlc1v-LacZ+/− and Fgf10+/−;Mlc1v-LacZ+/− lungs to determi
β-gal expression indicates both Fgf10 expression in the mesenchyme (black arrow
staining is detected throughout the epithelium of E13.5 control lung (white arrow) ind
(H) Decrease LacZ staining in Fgf10 hypomorphic lung epithelium (white arrow) in
LacZ expression in the mesenchyme (black arrowhead) corresponds to a defect in th
2005). (J) Vibratome section of the lung shown in panel H. (K, L) IHC for β-cate
epithelium. (M, N) IHC for β-catenin in E12.5 Fgf10 hypomorphic lung showing man
e – epithelium, m – mesenchyme, wt – wild type (Fgf10+/−), mt – mutant.characterized by a decrease in epithelial branching (Figs. 1C–
F). Consistent with our hypothesis that this phenotype results
from reduced Fgf10 levels, a similar phenotype was observed
in transgenic lungs over-expressing Sprouty2, a negative
regulator of FGF10 signaling (Mailleux et al., 2001). Primary
lobe formation in the mutant lungs was generally not affected,
except for the accessory lobe, which was absent in 9 of the 52
Fgf10+/+;Mlc1v-LacZ+/− lungs generated (see arrow in Figs.
1G, H). In addition, the remaining lobes in mutant lungs were
substantially smaller in volume than their littermate controls.
In order to rule out general growth retardation as the cause for
the hypoplastic lungs, the body weight (Fig. 1I) and lung weight
(data not show) of control (Fgf10+/−) and Fgf10 hypomorphic
embryos at different developmental stages were measured (the
number of embryos examined were n=3 at E14.5, n=5 at E17.5
and n=7 at birth, for control and mutant). While the body weight
between control and mutant embryos were not significantlyduction of canonical Wnt activation. (A–D) PCNA staining was used to monitor
ck arrow heads indicate PCNA labeled cells. (C) Note the specific decrease in
in cell proliferation is observed in mutant lungs. (E–J) The TOPGAL allele was
ne the level of activation of canonical Wnt signaling at E13.5. In this experiment,
head) and TOPGAL expression in the epithelium (white arrow). (E–F) LacZ
icating activeWnt signaling. (G) Vibratome section of the lung shown in panel E.
dicates reduced Wnt signaling. Note the previously described increase in Fgf10/
e engagement of the PSMC progenitors into the SMC lineage (Mailleux et al.,
nin in E12.5 control lung showing strong nuclear β-catenin expression in the
y blue nuclei in the epithelium indicating decreased nuclear β-catenin activation.
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P=0.05 at E17.5 and P=0.26 at birth), there was a clear
reduction in the lung weight of the mutant embryos compared to
the littermate controls at the three stages examined (7.5 mg±2.8,
16.8 mg± 2.1; 20,2 mg±0.6 vs. 13.7 mg±2.1, 34.8 mg±10.6,
45.7 mg±15 at E14.5, E17.5 and birth, respectively, Pb0.01 for
all three stages examined). This observation is confirmed by the
calculation of normalized wet weight ratios (wet weight of the
lung divided by the wet weight of the embryo; 1.7±0.1%, 1.9±
0.4% and 1.7±0.4% for the Fgf10+/−;Mlc1v-LacZ+/−mutants at
E14.5, E17.5 and birth, respectively; versus 2.9±0.7%, 3.5±
0.7% and 3.4±1.0% for the corresponding control embryos or
pups, respectively, Fig. 1J). The differences observed at each
stage are statistically significant (Pb0.01 for all three stages
examined). Thus, the lung growth defects observed in Fgf10
hypomorphic embryos are not linked to general growth
retardation.
Fgf10+/−;Mlc1v-LacZ+/− compound heterozygous lungs
display decreased epithelial proliferation and reduction in
canonical Wnt activation
Analysis of PCNA positive cells as a read out for
proliferation was carried out in control and mutant lungs at
E14.5 and E17.5 (Figs. 2A–D). At E14.5, epithelial
proliferation is drastically reduced in the mutant vs. control
lung (11.0±2% vs. 26.4±4.1%; n=3 for each genotype,Fig. 3. Analysis of epithelial differentiation in Fgf10+/−;Mlc1v-LacZ+/− lungs re
immunohistochemistry showing a decrease in SP-B expression in newborn Fgf10+/−;
SP-B labeled cells per section was analyzed. The difference observed between Fgf
Immunohistochemistry with TTF-1 antibody showing a decrease in TTF1 expression
number of TTF-1 labelled cells per section was analyzed. The difference observed bet
P0 – post natal day 0.Pb0.05). Interestingly, mesenchymal proliferation is not
affected in mutant (Fig. 2C; 5.6±1.4% vs. 5.4±1.2%,
respectively). The decreased proliferation in the epithelium
is associated with a lower number of P-ERK positive cells in
the Fgf10 hypomorphic lung epithelium (47% and 38%
decrease in the distal epithelium of Fgf10 hypomorph vs.
control lung at E13.5 and E14.5, respectively, n=3, data not
shown, Pb0.05). At E17.5, we could no longer distinguish
between epithelial and mesenchymal cells. A general reduc-
tion in cell proliferation in the mutant is observed (32.8±8%
vs. 21.6±4.5%; n=3 for each genotype; Pb0.05). Wnt
signaling is crucial during lung development to control the
maintenance and proliferation of epithelial progenitors at least
up to E14.5 (De Langhe et al., 2005; Mucenski et al., 2003).
We therefore examined the status of canonical Wnt signaling
in Fgf10+/−; Mlc1v-LacZ+/− lungs by genetically introducing
the TOPGAL allele into these mice. Previous studies indicate
that canonical Wnt signaling can be detected in the epithelium
of the lung using the TOPGAL reporter mice (De Langhe et
al., 2005; Okubo and Hogan, 2004; Shu et al., 2005), where
β-galactosidase expression is a reporter for canonical Wnt
signaling activation (DasGupta and Fuchs, 1999). Figs. 2E–J
show that reduction in FGF10 signaling results in drastic
down regulation of canonical Wnt signaling in the distal lung
epithelium at E13.5 (n=3 for each genotype). β-catenin
staining at E12.5 shows decreased nuclear β-catenin expres-
sion in the Fgf10 hypomorph vs. control lung (Figs. 2K–N).veals decreased expression of SP-B and TTF-1. (A–B) SP-B expression by
Mlc1v-LacZ+/− lungs (B) compared to control (Fgf10+/−) (A). (C) The number of
10+/−;Mlc1v-LacZ+/− (B) and control lung (A) is significant (pb0.01). (D–E)
in newborn Fgf10+/−;Mlc1v-LacZ+/− lungs (E) compared to control (D). (F) The
ween Fgf10+/−;Mlc1v-LacZ+/− (E) and control lungs (D) is significant (pb0.03).
Fig. 4. Fgf10+/−;Mlc1v-LacZ+/− lungs are not functional at birth. (A)
Histological section of E17.5 control (Fgf10+/−) lung depicting the canalicular
stage. (B) Section of E17.5 Fgf10+/−;Mlc1v-LacZ+/− lung. Note the larger distal
airways in the mutant lung suggesting a potential defect in the septation process.
(C) Dissected left lobe of a control (Fgf10+/−) lung at P2 (post natal day 2). (D)
Dissected left lobe of Fgf10+/−;Mlc1v-LacZ+/− lung at P2. Note the extremely
dilated airways of this P2 survivor. (E) H&E staining of the control lung shown
in panel C. (F) H&E staining of the Fgf10+/−;Mlc1v-LacZ+/− lung shown in
panel D. The mutant lung exhibits very dilated airways and thin mesenchyme.
(G) Survival curve of Fgf10+/−;Mlc1v-LacZ+/− (n=12) showing that more than
80% of the pups die during the first 24 h. (H and I) Morphometric analysis of the
lung. MLI, mean linear intercept; RAC, radio-alveolar count. IncreasedMLI and
decreased RAC in mutant indicate dilation of the distal airways.
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mesenchyme is upstream of Wnt signaling in the epithelium.
Fgf10+/−;Mlc1v-LacZ+/− compound heterozygous lungs
display reduced SP-B- and TTF-1-positive cells
Immunohistochemistry was used to evaluate potential
epithelial differentiation defects in Fgf10+/−;Mlc1v-LacZ+/−
vs. Fgf10+/− (control) lungs at birth. Antibodies against
Surfactant proteins SP-A, SP-B and SP-C as well as the
general lung epithelial marker TTF-1, were used. A general
reduction in the number of epithelial cells positive for these
markers was detected in mutant lungs (data not shown for SP-
A and SP-C). In particular, the percentile of cells positive for
Surfactant Protein B was reduced by 40% in mutant vs.
control (Fgf10+/−) lungs (Figs. 3A–C; 12.0±0.2% vs. 18.0±
0.2%, respectively, Pb0.001). Interestingly, it has been
reported that the SP-B gene mutation in human is neonatal
lethal (Nogee et al., 1994). Therefore, the reduction in
Surfactant Protein B expression could explain some of the
respiratory failures observed at birth. However, we cannot
conclude that epithelial differentiation per se is affected as we
also observe a comparable reduction in the percentile of cells
positive for the general epithelial marker TTF-1 in the mutant
vs. control lung (Figs. 3D–F; 25.0±1.0% vs. 42.0±5.0%,
respectively; n=3 for each genotype, Pb0.01). Interestingly
the ratio SP-B: TTF1 in control and mutant lungs is also
similar (43% vs. 48%, respectively) suggesting that the
reduction in the percentile of cells positive for SP-B and
TTF-1 in the mutant lung reflected a general decrease in
epithelial proliferation as observed at earlier stages (Fig. 2).
Similar observation has been made with the ratio of SP-C:
TTF1 (60% vs. 55% in control vs. mutant lungs).
Fgf10+/−;Mlc1v-LacZ+/− compound heterozygous lungs
display inhibition of secondary septa formation accompanied
by respiratory failure at birth
Histological analysis of the control and Fgf10+/−; Mlc1v-
LacZ+/− lungs at E13.5 and E14.5 showed no abnormalities in
the proximal–distal patterning of the lung epithelium. In both
control and transgenic lungs, the bronchiolar proximal
epithelium was columnar, whereas the distal respiratory
epithelium was low cubical (data not shown). At E17.5,
seven out of ten lungs from Fgf10+/−;Mlc1v-LacZ+/− embryos
displayed overly expanded distal airways with readily apparent
defects in the septation process (compare Figs. 4A and B).
Similar defects were found at postnatal stages (Figs. 4D–F).
These changes in peripheral pulmonary alveolar size were
quantified at E17.5 and P2 by morphometric measurement of
mean linear intercepts (MLI) and radial-alveolar count (RAC)
(Chen et al., 2005; Figs. 4H, I). Statistically significant
increased MLI and associated decreased RAC in mutant vs.
control (Pb0.001 for the two stages examined) indicate
dilation of the distal airways and failure to undergo secondary
septation. These structural defects in the respiratory airways
were accompanied by early lethality. Out of 12 pups analyzedafter birth, 9 (80%) died within 24 h, 3 died within 48 h (Fig.
4G). All of them exhibited severe gasping indicating
respiratory distress. Interestingly, the 3 pups that survived
more than 1 day after birth did not grow (data not shown) and
died 48 h after birth probably as a consequence of respiratory
failure as well as limb abnormalities (Veltmaat et al., 2006 and
data not shown) and gut defects (Sala et al., 2006).
Fgf10+/−;Mlc1v-LacZ+/− compound heterozygous lungs
display reduced alveolar smooth muscle cell formation
Immunofluorescence for α-smooth muscle actin (α-SMA)
was used to detect alveolar smooth muscle cells at E18.5 in the
respiratory airway. Fig. 5A shows the expression of α-SMA in
E18.5 control lungs. SMA expression was severely reduced in
243S.K. Ramasamy et al. / Developmental Biology 307 (2007) 237–247corresponding Fgf10+/−;Mlc1v-LacZ+/− lungs indicating defec-
tive alveolar smooth muscle cell formation (n=3 for each
genotype). In addition, in situ zymogram assays using
fluorescein isothyocyanate labeled gelatin to detect gelatinase
activity (corresponding to MMP2 and MMP9) was also
performed. In this assay, the gelatin with a fluorescent tag
does not fluoresce unless it is cleaved and the reaction product is
visualized using fluorescence microscopy. Smooth muscles in
control lung exhibit a high level of MMP activity (Fig. 5C)
while a clear reduction in gelatinase activity is observed in the
Fgf10+/−;Mlc1v-LacZ+/− lung (Fig. 5D). In agreement with
reduced formation of smooth muscle cells in Fgf10+/−;Mlc1v-
LacZ+/− lung, Elastin deposition was also decreased in the
mutant lung compared to the control (data not shown). Thus the
results indicate that there is a defect in the formation of alveolar
smooth muscle cells in Fgf10+/−;Mlc1v-LacZ+/− lungs.
Fgf10+/−;Mlc1v-LacZ+/− compound heterozygous lungs
display reduced vascular development
We have investigated potential defects in the development
of the vascular system in Fgf10 hypomorphic lungs using
light microscopy, immunofluorescence and vascular casts.
Figs. 6A and B show marked reduction in the number of red
blood cells present in the E13.5 Fgf10+/−;Mlc1v-LacZ+/− vs.
Fgf10+/− (control) lungs. A general decrease in the expression
of PECAM, a marker for endothelial cells, was observed in
E14.5 Fgf10+/−; Mlc1v-LacZ+/− vs. control lungs (n=3 for each
genotype). Antibodies against the extracellular matrix protein
Laminin were also used to visualize the status of the
microvasculature in the lung mesenchyme during the pseudo-Fig. 5. Fgf10+/−;Mlc1v-LacZ+/− lungs display reduced alveolar smooth muscle
cell formation. (A, B) Immunohistochemistry with α-smooth muscle alpha actin
(α-SMA) antibody in control (A) and Fgf10+/−;Mlc1v-LacZ+/− P1 lung sections
(B). Note the drastic decrease in α-SMA in the respiratory airways of the mutant
lung. (C, D) Corresponding staining for Gelatinase activity (see Materials and
methods for details) in control (C) and Fgf10+/−;Mlc1v-LacZ+/− lungs (D). Note
the decrease in Gelatinase activity in the mutant lung, especially around the
bronchi (arrows) and in the respiratory airway.glandular stage (Fig. 6E). Formation of the microcapillaries in
Fgf10+/−;Mlc1v-LacZ+/− lung was impaired (Fig. 6F). Finally,
vascular corrosion casts of the control and mutant lungs at E18.5
indicate a clear simplification of the vascular tree (Fig. 6G–g′;
n=2 for control and Fgf10+/−;Mlc1v-LacZ+/−). At P2, all of
the lungs examined exhibited large hemorrhagic areas (compare
Figs. 6H and I). Such defects were already observed at E17.5
(Fig. 1H).
Decreased alveolar smooth muscle formation and reduced
vascular development in Fgf10+/−;Mlc1v-LacZ+/− compound
heterozygous lungs are associated with decreased expression
of Pdgfa and Vegfa
We performed real-time PCR quantification of mRNA
expressed in the Fgf10+/−;Mlc1v-LacZ+/− vs. Fgf10+/− lungs.
Since the Fgf10+/−;Mlc1v-LacZ+/− lungs exhibited defects in
vascular development and alveolar smooth muscle cell forma-
tion, expression levels of related genes were determined. Fig. 7
shows representative real-time PCR results for the relative
expression of Fgf10, Vegfa, Pdgfa, and Pdgfb in Fgf10+/−;
Mlc1v-LacZ+/− vs. Fgf10+/− lungs. Consistent with previously
reported results, we observe a 27% decrease in Fgf10 expression
(Mailleux et al., 2005). Vegfa is expressed by the distal lung
epithelium and acts on the adjacent endothelial cells, expressing
VEGF-R to stimulate their proliferation (Del Moral et al.,
2006a,b).Vegfa expression was reduced by 28% in the Fgf10
hypomorphic lungs compared to control lungs. Pdgfa and Pdgfb
are also expressed by the distal lung epithelium. These growth
factors act on the alveolar smoothmuscle cell progenitors present
in the mesenchyme to induce their proliferation (Bostrom et al.,
1996; 2002). Pdgfa and Pdgfb expression were reduced about
60% and 16%, respectively. The expression of Hif1a and Glut1,
as indicators of potential hypoxic conditions in lung tissues
(Mobasheri et al., 2005), was not significantly changed between
Fgf10+/− and Fgf10+/−;Mlc1v-LacZ+/− at E14.5. These results
support the conclusion that changes in gene expression in the
Fgf10+/−;Mlc1v-LacZ+/− lungs are solely the consequence of
decreasing Fgf10 expression and not due to hypoxia.
Discussion
Fgf10−/− embryos display lung agenesis precluding func-
tional analysis of Fgf10 during subsequent lung development.
Here, we show that, in addition to its use as a reporter for Fgf10
expression, the Mlc1v-LacZ transgenic line also represents a
hypomorphic allele of Fgf10. This allowed us to determine the
in vivo role of Fgf10 during the later phases of lung
development. Newborn Fgf10+/−;Mlc1v-LacZ+/− compound
heterozygote mice exhibit severe respiratory defects and most
die within 24 h of birth. During embryogenesis, the Fgf10+/+;
Mlc1v-LacZ+/− lungs display significant hypoplasia, associated
with dilated distal airways. Analysis of vascular development
shows a reduction in PECAM expression at E14.5. This
reduction is associated with simplification of the vascular tree
at E18.5. E18.5 mutant lungs also display reduced expression of
α-SMA in the respiratory airways indicating abnormal alveolar
Fig. 6. Fgf10+/−;Mlc1v-LacZ+/− lungs display reduced vascular development. (A, B) E13.5 control (A) and Fgf10+/−;Mlc1v-LacZ+/− (B) lungs. Note the reduction in
the presence of red blood cells in the mutant lung. (C, D) PECAM staining in control (C) and mutant (D) lung. Note the reduction in PECAM staining in the mutant. (E,
F) Immunofluorescence with anti-Laminin antibodies on control (E) and mutant (F) E14.5 lungs. Note the abundant microvasculature in the mesenchyme of the control
lung and the drastic reduction in development of the microvasculature in the mutant lung. DAPI: blue staining. (G) Corrosion vascular cast of control and mutant E18.5
lungs. Note the reduced complexity of the vascular tree in the mutant lung. (g, g′) Corresponding high magnification of the peripheral part of the lung casts indicated in
G by boxes. (H, I) Dissected left lobe of control (H) and mutant (I) P2 lungs. Note the large hemorrhagic areas in the mutant lung supporting the previously reported
vascular defects.
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a decrease in Vegfa and Pdgfa expression, both expressed in the
epithelium.Fig. 7. Decreased alveolar smooth muscle formation and reduced vascular
development in Fgf10+/−;Mlc1v-LacZ+/− compound heterozygous lungs are
associated with decreased expression of Pdgfa and Vegfa. Real-time PCR was
used to quantify and compare the expression of key genes in Fgf10+/−;Mlc1v-
LacZ+/− vs. Fgf10+/− lungs at E14.5. Representative real-time PCR data are
presented as ratio of gene expression in mutant vs. control lung.Fgf10 dosage is important for proper lung development
The notion that appropriate levels of Fgf10 are needed for
normal lung development to occur has been unclear so far.
Our results indicate that the lungs of Fgf10+/− (control) mice
are phenotypically normal. However, if Fgf10 levels decrease
by 30% compared to heterozygous levels, distal lung
hypoplasia occurs. This is a likely consequence of significant
reduction in epithelial proliferation in the Fgf10 hypomorph
vs. control lung. Evidence is accumulating that Fgf10 dosage
is critical for proper development of certain organs while
others remain unaffected. The importance of Fgf10 dosage for
the development of salivary gland and lacrimal gland in
humans has been shown (Entesarian et al., 2005). Individuals
with autosomal dominant aplasia of lacrimal and salivary
glands (ALSG) exhibit hypoplastic or missing parotid and
submandibular glands. ALSG was mapped to 5p13.2–5q13.1,
which includes the FGF10 gene. Subsequently, all family
members with ALSG were found to be heterozygous for
Fgf10. Complementary studies in adult Fgf10+/−mice revealed
that Fgf10 heterozygotes have no parotid and smaller subman-
dibular glands (Jaskoll et al., 2005). Our recent results further
demonstrate that the morphogenesis of the mammary glands and
distal region of the colon are also Fgf10 dose-dependent
(Veltmaat et al., 2006; Sala et al., 2006).
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Our results show that Fgf10+/−;Mlc1v-LacZ+/− pups exhibit
severe lung hypoplasia as a result of reduced Fgf10 expression.
The Fgf10+/−;Mlc1v-LacZ+/− lungs displayed decreased num-
bers of SP-A, SP-B and SP-C expressing cells at birth,
suggesting that the development of the type-II alveolar cell
lineage may be affected. However, as the ratio SP-B :TTF1
(TTF1 being a general marker of lung epithelial cells) between
Fgf10+/− and Fgf10+/−;Mlc1v-LacZ+/− lung is similar, it is
unlikely that the decrease in surfactant protein (SP)-positive
cells reflects a defect in epithelial differentiation. Our results
suggest that the decrease in epithelial cell proliferation during
the pseudoglandular stage is the underlying cause of the
reduction in SP-positive cells.
Many in vitro studies imply FGFs as signals of proliferation
and differentiation (for reviews see Cardoso, 2001; Cardoso and
Lu, 2006; Warburton et al., 2000). In vivo, the loss of function
studies of Fgfr2b or Fgf10 show clearly that this signaling
pathway is vital in the development of the bronchial tree structure
(Arman et al., 1999; De Moerlooze et al., 2000; Min et al., 1998;
Sekine et al., 1999). Nevertheless, the phenotypes of the null
mutants make it impossible to establish the functional role of
FGF10 and FGFR2b in late stages of pulmonary development. In
the case of Fgfr2b, the inducible over-expression of the soluble
dominant negative FGFR2b receptor from the end of the
pseudoglandular phase (E14.5) disturbs alveogenesis after
birth. By contrast, a similar inhibition of FGFR2b signals after
birth does not lead to a defect in alveolar formation suggesting
that FGFR2b signaling is not needed for lung homeostasis
(Hokuto et al., 2003). The authors reported that FGFR2b
signaling is indeed critical during the early pseudoglandular
stage. Decrease in FGFR2b signaling during this early develop-
mental phase impacts negatively alveogenesis. Interestingly,
other FGFR2b ligands (FGF1, 3, 7) are expressed from E13.5
onwards in lung, either in the epithelium or the mesenchyme
(Bellusci et al., 1997; Cardoso, 2001; Lebeche et al., 1999).
There are therefore many FGFR2b ligands that could potentially
compensate for the loss of Fgf10. However, Fgf10 hypomorphic
mice have alveolar defects, as the likely consequence of events
taking place during early embryonic development, when Fgf10
is the only functional FGFR2b ligand expressed in the lung. Our
results therefore demonstrate that FGF10 plays a unique function
in the E9.5–E13.5 pseudoglandular period specifically in the
amplification of pulmonary epithelial progenitors.
FGF10 indirectly controls the formation of the alveolar smooth
muscle cells
A similar emphysematous-like, non-inflammatory lung
phenotype and postnatal death has been described for the Elas-
tin and Mmp-2 null mice (Kheradmand et al., 2002; Wendel et
al., 2000). In 15% of Mmp-2−/− newborns, a syndrome of
acute respiratory distress is associated with improper deposi-
tion of elastin fibers (Kheradmand et al., 2002). Interestingly, a
specific decrease in gelatinase activity at birth in Fgf10+/−;
Mlc1v-LacZ+/− lung mesenchyme was revealed by in situzymography and is associated with diminished SMA expres-
sion and Elastin deposition. These data suggest that reduced
Fgf10 expression disturbs the formation of the smooth muscle
cells in pre-alveolar structures, possibly reflecting hypoplasia
of the alveolar SMC progenitors. This conclusion is supported
by our observation that Pdgfa expression is strongly decreased
in Fgf10+/−;Mlc1v-LacZ+/− lungs. Interestingly, Pdgfa has
also been shown to be downstream of canonical Wnt signaling
in the lung epithelium (De Langhe et al., 2005). In addition, β-
catenin has been shown to be a downstream target of FGF10 in
the lung epithelium (Lu et al., 2005). This is in harmony with
the results of our recent Affymetrix arrays showing a 13%
decrease in β-catenin expression in Fgf10 hypomorph vs.
control lung at E14.5 (data not shown). However, it is unlikely
that decreased transcription of β-catenin per se is enough to
explain the reduction in Wnt signaling observed in the Fgf10
hypomorphic lungs (Fig. 2). Our results show indeed a
decrease in nuclear β-catenin localization in the epithelium of
Fgf10 hypomorph vs. control lungs (Fig. 2). It has recently
been shown that the well-known PI3K/AKT pathway is
capable, via the phosphorylation of β-catenin on serine 522, to
increase the amount of nuclear β-catenin (He et al., 2007). It is
therefore likely that in the lung epithelium, FGF10 controls β-
catenin signaling in this way rather than at the level of the
transcription of the β-catenin gene. More work will have to be
done to determine the exact mechanism of action of FGF10 on
the Wnt/β-catenin signaling. Our result that TOPGAL
expression is decreased in Fgf10+/−;Mlc1v-LacZ+/− lungs,
therefore strongly suggests that FGF10, upstream of β-catenin
signaling, controls Pdgfa expression in the lung epithelium.
FGF10 is a key regulator of epithelial morphogenesis and
vascular development
Decreased PECAM and Laminin expression at E14.5 in
Fgf10 hypomorphic lungs suggest that the simplified vascular
tree observed later on, at E18.5, is likely the consequence of
abnormal vascular development starting early during the
pseudoglandular stage. Interestingly, we have demonstrated
that lung development during the pseudoglandular stage is
under the unique control of Fgf10. Our results therefore suggest
a link between mesenchymal FGF10, which acts directly on the
epithelium and the development of the vascular system. This
observation has important implications as epithelial morpho-
genesis, mostly mediated by FGF10, has to be tightly controlled
with vascular development to obtain a functional lung at birth.
Our results indicate that there is a 28% decrease in Vegfa
expression in the Fgf10 hypomorph vs. control lung. Interest-
ingly, a similar decrease in TTF1 expression is observed in the
mutant lungs indicating that the decrease in Vegfa is due to the
reduction in the number of epithelial cells and not because
FGF10 controls directly, at the transcriptional level, Vegfa
expression in the epithelium.
In conclusion, our results indicate that FGF10 plays a crucial
role throughout the first half of the pseudoglandular stage in
maintaining the activation of the Wnt canonical pathway in
epithelial progenitor cells and regulating their proliferation. In
246 S.K. Ramasamy et al. / Developmental Biology 307 (2007) 237–247addition, we have demonstrated that FGF10 is essential in
coordinating alveolar smooth muscle cell formation and
vascular development.
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